224 related articles for article (PubMed ID: 30413901)
1. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
Zeidan AM; Giri S; DeVeaux M; Ballas SK; Duong VH
Ann Hematol; 2019 Feb; 98(2):339-350. PubMed ID: 30413901
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
3. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
4. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong SA; Leitch HA
Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
[TBL] [Abstract][Full Text] [Related]
6. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
[TBL] [Abstract][Full Text] [Related]
7. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis.
Yang Y; Tang Z; An T; Zhao L
Medicine (Baltimore); 2019 Oct; 98(40):e17406. PubMed ID: 31577751
[TBL] [Abstract][Full Text] [Related]
8. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
9. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
10. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
11. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
12. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
13. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
14. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
15. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM; Pullarkat VA; Komrokji RS
Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
[TBL] [Abstract][Full Text] [Related]
16. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Merkel DG; Nagler A
Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
[TBL] [Abstract][Full Text] [Related]
17. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Steensma DP; Gattermann N
Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
[TBL] [Abstract][Full Text] [Related]
18. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
Leitch HA; Chan C; Leger CS; Foltz LM; Ramadan KM; Vickars LM
Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
[TBL] [Abstract][Full Text] [Related]
19. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mitchell M; Gore SD; Zeidan AM
Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
